131I在复发性甲状腺乳头状癌临床诊治中的价值

甲状腺乳头状癌（PTC）总体预后良好，但首次治疗后仍可能有高达20%~30%的患者复发，并因此导致预后不良和治疗困难。¹³¹I是初治中高危风险PTC患者术后重要的辅助治疗手段，仍可在复发性PTC诊治中发挥重要作用，诊断方面可帮助早期发现并准确定位复发灶、评估摄碘能力、指导制定治疗方案；治疗上可作为微小复发灶根治性治疗、可手术切除病灶再次术后辅助治疗和晚期不可切除病灶姑息治疗的一部分。本文重点综述131I在复发PTC再次术后辅助治疗中的价值。

Clinical Value of 131I in Diagnosis and Treatment of Recurrent Papillary Thyroid Carcinoma

The papillary thyroid cancer (PTC) patients have general good prognosis, but the relapse occurred in 20%-30% patients after initial treatment, which resulted in poor prognosis and treatment difficulty. ¹³¹I can act as a part of postoperative adjuvant therapy for the initial standard treatment of middle- or high-risk PTC patients, and it still could play important roles in the diagnosis and treatment of recurrent PTC. ¹³¹I can contribute to early detection, accurate location and iodine uptake evaluation of recurrence foci and is helpful for the subsequent treatment scheme. 131I can serve as a part of radical treatment for small recurrent foci, postoperative adjuvant treatment for resectable lesions and palliative treatment for unresectable ones. This paper reviews the value of 131I treatment as the adjuvant therapy followed by reoperation in recurrent PTC.